Ciliary Neurotrophic Factor (CNTF)

05/01/2006 - "Thus, our findings further show that the antiobesogenic effects of CNTF in the periphery result from direct effects on skeletal muscle, and that these peripheral effects are not suppressed by diet-induced or genetic models of obesity, an essential requirement for the therapeutic treatment of obesity-related diseases."
01/01/2022 - "Efficacy of PEGylated ciliary neurotrophic factor superagonist variant in diet-induced obesity mice."
01/01/2022 - "Studies involving a higher number of selected patients may reveal circulating CNTF and/or CNTFRα as potential novel diagnostic and/or prognostic markers of obesity, diabetes and associated diseases."
01/01/1998 - "Given the potential of CNTF to influence energy homeostasis, this study was undertaken to determine whether variability in the CNTF gene is associated with human obesity. "
01/01/2022 - "In conclusion, endogenous CNTF signalling is activated in human obesity and may help counteract some adverse effects of obesity. "

05/01/2004 - "In contrast to the European study, we were unable to detect a significant association between CNTF genotype and body weight in the BLSA (P=0.49), the STORM (P=0.28), or the combined samples (P=0.72). "
05/01/2004 - "A recent study in a European cohort demonstrated a significantly higher body weight and body mass index (BMI) in older males homozygous for the CNTF null allele (A/A genotype). "
01/01/2022 - "In addition to its role in the nervous system, CNTF regulates the balance of energy metabolism and the administration of CNTF induces body weight loss. "
06/27/2014 - "Moreover, therapeutic application of CNTF reduced body weight in mice and humans. "
06/01/2009 - "In contrast to subcutaneous rhCNTF, which caused a 20-30% decrease in body weight in neonatal rats between postnatal days 2 and 7 together with a considerable fat mobilization in brown adipose tissue, TAT-CNTF lacked such side effects. "

10/01/2016 - "To evaluate the long-term efficacy of ciliary neurotrophic factor delivered via an intraocular encapsulated cell implant for the treatment of retinitis pigmentosa. "
09/09/2014 - "Thus far, CNTF has failed to demonstrate rod protection in trials for human retinitis pigmentosa. "
08/01/2013 - "Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa."
04/01/2007 - "This study was conducted to test whether CNTF prevents photoreceptor cell loss in XLPRA2, an early onset canine model of X-linked retinitis pigmentosa caused by a frameshift mutation in RPGR exon ORF15. "
10/01/2016 - "Long-term Follow-up of Patients With Retinitis Pigmentosa Receiving Intraocular Ciliary Neurotrophic Factor Implants."

03/07/2006 - "When the implants were removed after 6 months, they contained viable cells with minimal cell loss and gave CNTF output at levels previously shown to be therapeutic for retinal degeneration in rcd1 dogs. "
09/01/2003 - "Thus, CNTF may be a useful treatment for human antibody-mediated retinal degeneration."
11/15/1998 - "These results suggest that continuous administration of CNTF could potentially be useful for the treatment of some forms of retinal degeneration."
04/06/2011 - "Larger studies of cone structure using high-resolution imaging techniques are urgently needed to evaluate the effect of CNTF treatment in patients with inherited retinal degenerations."
06/01/2002 - "The mechanisms for these side effects and proper doses of CNTF administration should be determined before human clinical trials are considered for the amelioration of inherited retinal degenerations with CNTF."

06/01/1995 - "We found that CNTF delayed the disease progression by increasing the survival time by 40% and by improving motor function as assessed by three behavioural tests. "
05/01/1996 - "The ALS CNTF Treatment Study (ACTS) clinical trial was a phase II-III randomized, placebo-controlled, double-blind study designed to evaluate the safety, tolerability, and efficacy of subcutaneous administration of recombinantly produced human CNTF (rHCNTF) in slowing disease progression in 730 patients with amyotrophic lateral sclerosis (ALS). "
08/01/1994 - "Thus, ciliary neurotrophic factor retarded the disease progression and improved muscle strength in this motor neuron disease model."
08/01/2006 - "Our results show that CNTF inhibits inflammation in the spinal cord, resulting in amelioration of the clinical course of experimental autoimmune encephalomyelitis during time of treatment."
03/01/1999 - "Although some factors such as ciliary neurotrophic factor and brain-derived neurotrophic factor slowed down the disease progression in animal models of motor neuron disease, phase III clinical trials showed no therapeutic effects for ALS patients treated with these factors. "